Relypsa
Pioneering advancements in cardiovascular and renal health with innovative polymeric drugs for iron deficiency and nephrology therapies.
General Information
BounceWatch is an independent company data service, not affiliated with Relypsa. To contact Relypsa, visit relypsa.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About Relypsa
Taxonomy: biotech, cardiovascular health, renal health, polymeric drugs, iron deficiency, nephrology, therapy, drug discovery, non-absorbed drugs, pharmaceuticals
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | $150.00M | 1 |
|
03 May 2016 |
| Post IPO Equity | $161.90M | - |
|
25 Feb 2015 |
| Post IPO Debt | $35.00M | 2 |
Silicon Valley Bank, Oxford Finance LLC
|
02 Jun 2014 |
| Venture Round | $2.60M | 3 |
|
01 Oct 2012 |
| Series C | $80.00M | 7 |
|
14 Aug 2012 |
| Private Equity Round | $62.40M | 7 |
|
01 Jul 2012 |
| Series B | $70.13M | 6 |
|
08 Aug 2011 |
| Series B | $70.00M | 6 |
|
13 Sep 2010 |
| Debt Financing | $4.00M | - |
|
03 May 2010 |
| Series A | $33.00M | 6 |
|
29 Oct 2007 |
Relypsa Alternatives & Competitors
View All Alternatives
Innovative solutions for precise, localized treatments in ear, nose, and throat care.
Driving advancements in respiratory health with innovative inhalable treatments.
FAQ About Relypsa
Source: BounceWatch company record for Relypsa, https://bouncewatch.com/company/relypsa, updated 27 December 2024. When citing, please name BounceWatch and link this page.
